Date post: | 02-Jul-2015 |
Category: |
Investor Relations |
Upload: | company-spotlight |
View: | 6,396 times |
Download: | 0 times |
Revolutionizing the Fight Against Cancers and Infectious Diseases
Dr. Joseph Kim President & CEO NASDAQ: INO
Forward Looking Statement
Our commentary and responses to your questions may contain forward-looking statements, including comments concerning clinical trials and product development programs, evaluation of potential opportunities, the level of corporate expenditures, the assessment of Inovio’s technology by potential corporate partners, capital market conditions, timing of events, cash consumption and other subjects. Information concerning factors that could cause actual results to differ materially from those set forth in our Annual Report on Form 10-K for the year ended December 31, 2013, our Form 10-Q for the quarter ended September 30, 2014, and other regulatory filings from time to time.
2
3
Inovio: creating the path to an active immunotherapy with broad clinical utility
• Lead DNA immunotherapy product, VGX-3100, meets phase II efficacy endpoints; technology breakthrough for active immunotherapy field
• First clinically meaningful efficacy from T cells generated EXCLUSIVELY in vivo
• De-risking of pipeline products
• Best T cell responses in published clinical studies
• Favorable safety profile
• Validating partnerships
First-in-Class Efficacy from an Active Immunotherapy
Human Papillomavirus
Low Grade Cervical
Pre-cancer (CIN 1)
High Grade Cervical
Pre-cancer (CIN 2/3)
VGX-3100 Phase II Data: Building New Market Opportunity
• Treat HPV-associated pre-cancers and cancers • Phase II controlled trial regressed high grade
cervical pre-cancer and cleared HPV • Fulfill unmet need, providing non-surgical
alternative for pre-cancerous lesions • Potential elimination of residual HPV in
untreated tissue • Advance into phase III for cervical pre-cancer
(CIN 2/3) in 2016 • Dominate post-HPV infection therapeutic
markets • Advance other HPV-associated pre-cancers
(vulvar, vaginal and anogenital neoplasias) and cancers (cervical, head and neck, and anogenital)
4
Disease Progression
Cervical Cancer
Phase II: Study Design
• 148 subjects: 19-55 year old females with high-grade cervical dysplasia (CIN2/3)
• HPV 16 and/or 18 positive • 6 mg VGX-3100 or placebo(IM followed by EP)
Placebo-controlled, Randomized, Double
Blind
• Regression of CIN2/3 to CIN1 or Normal at six months post third dose (Week 36) Primary Endpoint
• Regression of CIN2/3 to CIN1 or Normal and • Clearance of HPV 16 and/or 18 genotype
detected during screen Secondary Endpoint
5
0
10
20
30
40
50
60
Phase II: Efficacy Data Meets Primary and Secondary Endpoints
Histopathologic Regression to CIN1 or Normal (n=143)
49.5% (53/107)
30.6% (11/36)
Statistically significant difference (p=0.017; strata-adjusted)
Perc
ent
Histopathologic Regression to CIN1 or Normal AND Virological Clearance (HPV16 or 18) Incidence
(n=143)
0
10
20
30
40
50
60
40.2% (43/107)
14.3% (5/35)
Perc
ent
VGX-3100 Placebo VGX-3100 Placebo Statistically significant difference
(p=0.001; strata-adjusted)
• Efficacy data meets primary and secondary efficacy endpoints • High level of complete CIN 2/3 clearance • Robust HPV-specific T cell responses in majority of treated subjects, as in phase I • Treatment well-tolerated with only administration site redness • Data being published • Expect to initiate phase III trial in 2016 6
VGX-3100: Next Steps
EXPANSION OF HPV PROGRAM TO RELATED CANCERS AND PRE-CANCERS • Cervical cancer (Ph I/IIa initiated) • Head & neck (Ph I/IIa initiated)
• Anogenital cancers • VIN, PIN
ANALYSIS OF PHASE II DATA IN PROGRESS • Immunological analysis to further characterize T cell subsets is also
in progress. Phase II data will add to Phase I data which has already been extensively characterized (Bagarazzi, et al. Sci Transl Med 2012)
• Manuscripts are in preparation
PHASE III DEVELOPMENT UNDERWAY • Clinical and regulatory • Commercial EP device development • Quantitative market research
• Supply chain strategy • Pricing & reimbursement
7
T cell Antigen-specific killer T cell
Target cell
8
It’s All About the T Cells
• Inovio immunotherapies display best-in-class T cells in HIV and HPV human studies:
o Magnitude o Durability (memory) o “Killing tools”: granzyme and
perforin o Functional killing effect
• A new paradigm for generating
clinically relevant immune responses and efficacy
• Safe and well tolerated
CIN 2/3
Immuno-oncology Strategy: CIN 2/3 & Beyond
9
Broad Medical and Market Opportunities
Product Name
INTERNALLY FUNDED
Indication Preclinical Phase I Phase II
Vgx-3100
Ino-5150
Ino-1400
EXTERNALLY FUNDED
pennvax®
Ino-3510
Ino-8000
ino-1800
Phase III
10
INO-3112
INO-3112
Hepatitis C Therapeutic
Hepatitis B Therapeutic
influenza
Preventive
hiv
Preventive/ Therapeutic
Breast/lung / Pancreatic cancers
Therapeutic
Prostate cancer Therapeutic
Head & Neck Cancer Therapeutic
Cervical Cancer Therapeutic
Cervical dysplasia
Therapeutic
Preventive/ Therapeutic
Ebola
Aerodigestive Cancer Therapeutic
INO-3106
INO-4200
11
Cervical Dysplasia: Schiffman et al. Arch Pathol Lab Med (2003), Public Health England Cervical Cancer Screening Programme, Stoler et al. Anatomic Path (2011), Castle et al. JNCI (2005), Mayrand et al. NEJM (2007) Cancers: CDC, www.hpvcentre.net, WHO IARC
LOW GRADE
CERVICAL DYSPLASIA
(CIN1)
US: ~1,400,000
EU5: ~1,300,000
HIGH GRADE
CERVICAL DYSPLASIA
(CIN2/3)
US: 270,800
EU5: 267,400
CERVICAL CANCER
US: 11,818
EU5: 14,043
OROPHARY-NGEAL
CANCER
US: 11,726
EU5: 13,932
Incident cases in the US and EU5:
HPV-Caused Pre-Cancers & Cancers: VGX-3100
HPV-Associated Cancer Treatments Already Enrolling
Phase I/IIa’s: INO-3112 (VGX-3100 + IL-12 DNA immune activator); HPV 16/ 18 related disease
Cervical Cancer • 20 women with cervical carcinoma • Safety, tolerability, immunogenicity • Cervical histology • Treated after chemoradiation
Head & Neck Squamous Cell Carcinoma • 20 men/women • Safety, tolerability, immunogenicity • Anti-tumor effects & progression free
survival • Arm #1: treated before/after tumor
resection • Arm #2: treated after chemoradiation
12
hTERT-Associated Cancers: INO-1400
• Antigen: human telomerase reverse transcriptase (hTERT), an enzyme associated with cancer cell survival; overexpressed in 85% of cancers - potential “universal” cancer therapy
• (+/- IL-12 DNA immune activator)
• Phase I/IIa: 54 patients with breast, lung, or pancreatic cancers
• Safety, tolerability, immunogenicity
• Anti-tumor effects and progression free survival
• Trial launch: 4Q 2014
13
anthrax Louis Pasteur
Peter Kies CFO • Ernst & Young
• Experience with growth companies
Mark L. Bagarazzi, MD CMO • Clinical research experience incl. Merck
• Led clinical/regulatory for shingles and rotavirus vaccines; DNA vaccine expert
14
J.Joseph Kim, PhD President & CEO
• Decades of biotechnology/ pharma management
• Merck: hepatitis A and B vaccines manufacturing; HIV
vaccine (Ad5) R&D
Niranjan Y. Sardesai, PhD COO
• Extensive biotech management and product development
experience
• Led diagnostics development for mesothelioma, bladder
cancer, and ovarian cancer for Fujirebio Diagnostics
Management
anthrax Louis Pasteur
J.Joseph Kim, PhD • President & CEO, Inovio
Adel Mahmoud, PhD • Professor, Princeton University
• Former President, Merck Vaccines
• Responsible for Gardasil®, Zostavax®, Proquad® and Rotateq®
Morton Collins, PhD • General Partner, Battelle Ventures and Innovations Valley Partners
15
Simon X. Benito • Former Senior Vice President,
Merck Vaccine Division
Angel Cabrera, PhD • President, George Mason
University
• Former President, Thunderbird School of Global Management
Avtar Dhillon, MD Chairman, BOD
• Former President & CEO, Inovio Biomedical
Board of Directors
anthrax Louis Pasteur
Stanley A. Plotkin, MD • Developed rubella and rabies vaccines
• Oversaw Sanofi flu vaccine
• Emeritus Professor, Wistar Institute & University of Pennsylvania
Philip Greenberg, MD • Expert in T cell immunology
• Head, Immunology Program, Fred Hutchinson Cancer Research Center
16
Thomas S. Edgington, MD • Founded multiple biotech companies;
extensively published
• Emeritus Professor, Scripps Research Institute
Anthony W. Ford-Hutchinson, PhD
• Former SVP, Vaccines R&D, Merck
• Oversaw development: Singulair®, Januvia®, Gardasil®, Zostavax®,
Proquad® and Rotateq®
David B. Weiner, PhD Chairman
•“Father of DNA vaccines”
• Dept. of Pathology & Laboratory Medicine, University of Pennsylvania
Scientific Advisory Board
Financial Information
Cash, cash equivalents & short-term investments2 $ 100.9 M
Debt2 0 M
Cash runway 4Q 2017
Shares outstanding2 60.5 M
Recent share price1 $9.44
Market cap1 $ 571.1 M
NASDAQ: INO
1Nov 19, 2014 2Sep 30, 2014
17
Recent insider buying $2.75M
INTERNALLY FUNDED EXTERNALLY FUNDED
Ino-5150 1H 2015 Initiate phase I
Prostate cancer
Vgx-3100 2016 Initiate phase III Cervical dysplasia
INO-3112 2Q 2014 Initiated phase I/IIa
Head & Neck Cancer
18
Value Drivers
INO-3112 2Q 2014 Initiated phase I/IIa
Cervical Cancer
Ino-1400 4Q 2014 Initiate phase I/IIa
Breast/lung/ Pancreatic Cancer
PennVAX®
1Q 2015 Initiate PENNVAX-GP phase I HIV
Ino-8000 2015 Report interim phase I data Hepatitis C
Ino-1800 2015 Initiate phase I/IIa Hepatitis B
Ebola 1H 2015 Initiate phase I
INO-3106 3Q 2014 Initiated phase I
Aerodigestive Cancer
INO-4200
Best-in-class T cells to prevent, treat and cure
cancers and infectious diseases
Targeting broad range of
diseases and numerous
billion dollar markets
Breakthrough active immune
therapy technology with potential to save
lives
Validating partnership with Roche;
working toward more
deals
Phase II data shows clinically
significant efficacy
Investor Highlights
19
20
Revolutionizing the Fight Against Cancers and Infectious Diseases
Strain 1
Strain X
Strain 2
Antigen Y
Antigen Y Antigen Y
T Cells by Design: Antigen-Specific, Optimized, Best-in-Class
21
Identify gene sequence of selected antigen(s) from chosen strains/variants of the virus/cancer
Synthetically create optimal consensus gene sequence for the selected antigen – PATENTABLE
Insert SynCon® gene sequence for selected antigen into DNA plasmid.
SYNCON® DNA
Antigen consensus
sequence
DNA Plasmid
Designed to Break Tolerance or Provide Universal Protection
22
SynCon DNA plasmid ready to manufacture.
Electroporation Delivery Plays a Vital Role
23
DNA Immunotherapies: Disease-Specific T Cells by Design
It’s all about the T cells!
24
SynCon®+ Electroporation: Significant Antigen Expression
Ref: Sardesai & Weiner Curr. Opin. Immunol. 2011
• 1000x increase in cellular uptake and antigen production/ expression
• >500 patents globally
Intramuscular Intradermal
25
PENNVAX®: Highest CD8+ T Cell Responses for HIV Vaccine
Ref: Kalams et al JID 2013 26
A: 3X vaccination without EP B: 4X vaccination without EP C: 2x vaccination with EP (month 2) D: 3x vaccination with EP (month 4) E: Memory response (month 9)
A B C D E
• Best CD8+ T cell response in HIV clinical studies
• Durable T cell memory responses • Safe and well tolerated
0 1 2 3 4 5 6 7 8 9 Dosing Schedule (Months)
Inovio Beats Previous Gold Standard for T Cell Generation DNA/Electroporation vs Merck Ad5 Viral Vector (Non-Human Primates)
SIV Model: UPenn/Merck/Inovio Assay: Data Co-Published
T Cell ELISpot Assay T Cell Proliferation Assay
DNA + EP Ad5 DNA + EP Ad5
Ref: Hirao et al. Molecular Therapy, August 2010
Flow Cytometry Assay
27
Ad5 DNA + EP Ad5 DNA + EP
Combined Cohorts Individual Dose Cohorts
VGX-3100 Induces Robust and Durable T Cell Responses
Bagarazzi, Yan, Morrow et al. Sci Transl Med 4, 155ra138 (2012)
• 14/18 (78%) subjects responded to at least one antigen • 13/18 (72%) responded to at least two antigens • 9/18 (50%) responded to all four antigens
28
ELISpot Assay
0 1 2 3 4 5 6 7 8 9 Dosing Schedule (Months)
Bagarazzi, Yan, Morrow et al, Science Trans. Med. (2012)
HPV16-, HPV18-Specific IFN-γ Production
Multi-parameter flow cytometry: CD4, CD8 activation phenotype
29
HPV16-, HPV18-Specific CD107a, Granzyme B, Perforin
Bagarazzi, Yan, Morrow et al, Science Trans. Med. (2012)
CD8 cytolytic phenotype
30
VGX-3100 Flow Cytometry – Functional Killing Assays
Inovio Confidential Bagarazzi, Yan, Morrow et al. Sci Transl Med 4, 155ra138 (2012)
Quantitative Assay
Qualitative Assay
• Patient pre-VGX-3100 PBMC are targets, post-VGX-3100 PBMC are effectors • Quantitative - PBMC added irrespective of Ag-specific CD8 frequency • Qualitative - PBMC normalized to account for Ag-specific CD8 frequency • Measure granzyme B delivery to targets
31
Surgical Standard of Care for CIN2/3: LEEP
• High-voltage electrical arc at 100oC vaporizes a plane through the cervix, then fulguration using a cautery
• Black, particulate “coffee ground” discharge for weeks
IARC monograph 2003:Edited by J.W. Sellors and R. Sankaranarayanan 32
INO-1400: Potential Universal Cancer Therapy Targeting hTERT (overexpressed in 85% of cancers)
Yan J et al., Cancer Immunol Res. (2013) 33
Dharmapuri et al., Mol Ther. (2009)
T-cell generation: older generation DNA vaccine and electroporation device
SynCon® T-cell generation with CELLECTRA® electroporation device